Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 83

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 83
---
2025, which the Company is projecting will be insufficient to sustain
its operations through one year following the date that the financial statements are issued.

Additional
capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on
terms acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates
or cease operations. If we raise additional funds through the issuance of additional debt or equity securities it could result in dilution
to our existing stockholders, increased fixed payment obligations and these securities may have rights senior to those of our common stock
and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our
ability to incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business,
financial condition and prospects.

Financing
strategies we may pursue include, but are not limited to, the public or private sale of equity, debt financing or funds from other capital
sources, such as government or grant funding, collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements
with third parties. There can be no assurances additional capital will be available to secure additional financing, or if available, that
it will be sufficient to meet our needs on favorable terms. If we are unable to raise additional capital in sufficient amounts or on terms
acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates.
If we raise additional funds through the public or private sale of equity or debt financings, it could result in dilution to our existing
stockholders or increased fixed payment obligations and these securities may have rights senior to those of our common stock and could
contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to
incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating restrictions
that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial
condition and prospects.

33

Cash Flows

The following table summarizes
our cash flows for the periods indicated:

    Six Months Ended June 30, 
  
    (in thousands) 
    2025